Lung tissue and cells from the blood vessels that pass through the lungs derived from people with pulmonary arterial…
Articles by Steve Bryson, PhD
LungFit PH, Beyond Air’s device for administering nitric oxide therapy, has received European CE mark approval for persistent…
Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, a lung transplant, or hospitalization among adults with pulmonary…
Cereno Scientific has secured loan financing to continue developing CS1, its lead therapeutic candidate for pulmonary arterial hypertension…
Differences in Uptravi (selexipag) maintenance doses have no impact on the risk of hospitalization among adults with pulmonary…
People with pulmonary hypertension (PH) see worse outcomes following surgery to correct a hip fracture, a study shows. Among…
The U.S. Food & Drug Administration (FDA) has tentatively approved Alembic Pharmaceuticals‘ generic formulation of injectable selexipag as a…
A SIRT3 protein deficiency in skeletal muscles, which are attached to bones, was related to pulmonary hypertension associated with…
Enrollment has begun in a Phase 1b study of Tectonic Therapeutic’s TX45, an investigational treatment for people with…
Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO)…
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S.
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with…